Halothane is there still any place for using the gas as an anesthetic?

Hepatitis Monthly

Volumn 11, Issue 7, 2011, Pages 511-512

  Dabbagh, Ali ^a   Rajaei, Samira ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Halothane nanotechnology anesthesiology hepatitis

Indexed keywords

AMINOTRANSFERASE; DESFLURANE; ENFLURANE; HALOTHANE; ISOFLURANE; PROPOFOL; SEVOFLURANE;

AMINOTRANSFERASE BLOOD LEVEL; ANESTHESIA; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG SAFETY; EDITORIAL; HEPATITIS; HUMAN; LIVER FAILURE; LIVER METABOLISM; LIVER TOXICITY; MORTALITY; NANOMEDICINE;

EID: 79961076136     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Suckling CW. Some chemical and physical factors in the development of fluothane. Br J Anaesth. 1957;29(10):466-72.
2. Johnstone M. The human cardiovascular response to fluothane anaesthesia. Br J Anaesth. 1956;28(9):392-410.
3. Postoperative death after fluothane. Anesthesiology. 1958;19(4):562-3.
4. Brody GL, Sweet RB. Halothane anesthesia as a possible cause of massive hepatic necrosis. Anesthesiology. 1963;24:29-37.
5. Lindenbaum J, Leifer E. Hepatic necrosis associated with halothane anesthesia. N Engl J Med. 1963;268:525-30.
6. Whalen FX, Bacon DR, Smith HM. Inhaled anesthetics: an historical overview. Best Pract Res Clin Anaesthesiol. 2005;19(3):323-30.
7. You Q, Cheng L, Reilly TP, Wegmann D, Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology. 2006;44(6):1421-31.
8. Schuster M, Gottschalk A, Berger J, Standl T. A retrospective comparison of costs for regional and general anesthesia techniques. Anesth Analg. 2005;100(3):786-94, table of contents.
9. Forrest ML, Kwon GS. Clinical developments in drug delivery nanotechnology. Adv Drug Deliv Rev. 2008;60(8):861-2.
10. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol. 2006;533(1-3):341-50.
11. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-15.
12. Wang H, Cork R, Rao A. Development of a new generation of propofol. Curr Opin Anaesthesiol. 2007;20(4):311-5.
13. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A. 2010;107(42):17939-44.
14. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev. 2006;58(14):1456-9.
15. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008;26(8):442-9.
16. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
17. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
18. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces. 2008;66(2):274-80.